Renal Department and Nephrology Institute, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Institutes for Systems Genetics, West China Hospital, Sichuan University, Chengdu, China.
Front Immunol. 2023 Mar 20;14:1117995. doi: 10.3389/fimmu.2023.1117995. eCollection 2023.
The activated complement profile in IgA nephropathy (IgAN) is still unclear. Our study investigated the profile of urinary complements in IgAN patients and its correlations with clinical and pathological characteristics.
Urinary protein abundance was detected by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in 50 IgAN, 50 membranous nephropathy (MN), and 68 healthy controls (HC). Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to identify differentially expressed proteins in IgAN patients. The differentially expressed complement proteins were screened in IgAN patients, and their correlations with laboratory or pathological parameters were analyzed. Thereafter, 7 complement components were validated by enzyme-linked immunosorbent assay (ELISA) in the urine samples of 45 IgAN patients.
There were 786 differentially expressed proteins between IgAN and HC. KEGG analysis showed that differentially expressed urinary proteins in IgAN were enriched with complement. Of these, 67% of urinary complement protein abundance was associated with the estimated glomerular filtration rate. The urinary complement-related protein collectin12 (colec12), complement H factor (CFH), complement H factor-related protein 2 (CFHR2), and complement B factor (CFB) were positively correlated with serum creatinine; colec12, CFHR2, CFB, and C8g were positively correlated with glomerulosclerosis; CFH, CFHR2, C8g, and C9 were positively correlated with tubular atrophy/interstitial fibrosis.
Abnormally increased components of complement pathways significantly correlate with reduced renal function, proteinuria, and renal histological damage in IgAN. It could provide a potential biomarker panel for monitoring IgAN and provide clues for therapeutic choice targeting complement system of IgAN patients.
IgA 肾病(IgAN)中激活的补体谱仍不清楚。本研究调查了 IgAN 患者尿液补体谱及其与临床和病理特征的相关性。
采用液相色谱-串联质谱(LC-MS/MS)检测 50 例 IgAN、50 例膜性肾病(MN)和 68 例健康对照(HC)患者的尿液蛋白丰度。然后,进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)分析,以鉴定 IgAN 患者中差异表达的蛋白质。筛选 IgAN 患者中差异表达的补体蛋白,并分析其与实验室或病理参数的相关性。随后,采用酶联免疫吸附试验(ELISA)验证 45 例 IgAN 患者尿液中的 7 种补体成分。
IgAN 与 HC 之间有 786 种差异表达蛋白。KEGG 分析显示,IgAN 尿液中差异表达的蛋白质富含补体。其中,67%的尿补体蛋白丰度与估计肾小球滤过率相关。尿补体相关蛋白集落刺激因子 12(colec12)、补体 H 因子(CFH)、补体 H 因子相关蛋白 2(CFHR2)和补体 B 因子(CFB)与血清肌酐呈正相关;colec12、CFHR2、CFB 和 C8g 与肾小球硬化呈正相关;CFH、CFHR2、C8g 和 C9 与肾小管萎缩/间质纤维化呈正相关。
补体途径异常增加的成分与 IgAN 患者肾功能下降、蛋白尿和肾脏组织学损伤显著相关。这可能为监测 IgAN 提供潜在的生物标志物,并为 IgAN 患者靶向补体系统的治疗选择提供线索。